This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, S. Articles by Livingston, P. O. Search for Related Content PubMed PubMed Citation Articles by Zhang, S. Articles by Livingston, P. O.

Immune Sera and Monoclonal Antibodies Define Two Configurations for the Sialyl Tn Tumor Antigen¹

Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [S. Z. L. A. W., K. O. L., P. O. L.], Gastrointestinal Research Laboratory, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029 [S. O., S. H. I.], and Biomira, Inc., Research Centre One, Edmonton Research and Development Park, Edmonton, Alberta T6N 1E5 Canada [R. R. K., M. R., S. S. G., B. M. L.]

Sialyl Tn (sTn) is a mucin-associated carbohydrate antigen expressed in most types of human adenocarcinoma. Defining the configuration of tumor cell surface sTn recognized by antibodies is important for understanding the basis for the cancer cell specificity of sTn-reactive mAbs, for the development of more effective mAbs, and for designing cancer vaccines against sTn. In this study, we compared the immunogenicity of synthetic single sTn disaccharide epitopes and clusters [sTn(C)] of 3 sTn epitopes covalently linked via serine to keyhole limpet hemocyanin [KLH; sTn-KLH and sTn(C)-KLH, respectively]. The cell surface sTn configurations were analyzed with the use of sera from mice immunized with these neoglycoproteins and a panel of sTn-reactive mAb. Sera from mice immunized with sTn-KLH reacted in direct and inhibition assays with sTn-human serum albumin (HSA) but only weakly with sTn(C)-HSA, whereas sera from mice immunized with sTn(C)-KLH reacted with sTn(C)-HSA but not with sTn-HSA. Both anti-sTn and anti-sTn(C) sera reacted with ovine submaxillary mucin (a natural source of sTn) and with sTn-positive human tumor cell line LS-C but not with sTn-negative LS-B cells. With regard to the sTn-reactive mAbs, B72.3 reacted exclusively with clustered sTn, whereas mAb B195.3R11 reacted preferentially with unclustered sTn. Results with mAbs TKH2, B239.1, and CC49 were less clear, although all reacted more strongly with clustered sTn than with unclustered sTn. These results suggest that sTn is recognized at the tumor cell surface in at least two quite distinct configurations, as clustered and nonclustered arrays.

¹ This work was supported by NIH Grants CA61422, CA08748, CA52477, and CA52491 and The Chemotherapy Foundation.

² To whom requests for reprints should be addressed, at Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Received 1/19/95. Accepted 5/25/95.

This article has been cited by other articles:

				P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]

				T. A. Gilewski, G. Ragupathi, M. Dickler, S. Powell, S. Bhuta, K. Panageas, R. R. Koganty, J. Chin-Eng, C. Hudis, L. Norton, et al. Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21 Clin. Cancer Res., May 15, 2007; 13(10): 2977 - 2985. [Abstract] [Full Text] [PDF]

				M. Clement, J. Rocher, G. Loirand, and J. Le Pendu Expression of sialyl-Tn epitopes on {beta}1 integrin alters epithelial cell phenotype, proliferation and haptotaxis J. Cell Sci., October 1, 2004; 117(21): 5059 - 5069. [Abstract] [Full Text] [PDF]

				S. J. Keding and S. J. Danishefsky Natural Product Synthesis Special Feature: Prospects for total synthesis: A vision for a totally synthetic vaccine targeting epithelial tumors PNAS, August 17, 2004; 101(33): 11937 - 11942. [Abstract] [Full Text] [PDF]

				R. Lo-Man, S. Vichier-Guerre, R. Perraut, E. Deriaud, V. Huteau, L. BenMohamed, O. M. Diop, P. O. Livingston, S. Bay, and C. Leclerc A Fully Synthetic Therapeutic Vaccine Candidate Targeting Carcinoma-Associated Tn Carbohydrate Antigen Induces Tumor-Specific Antibodies in Nonhuman Primates Cancer Res., July 15, 2004; 64(14): 4987 - 4994. [Abstract] [Full Text] [PDF]

				S. F. Slovin, G. Ragupathi, C. Musselli, K. Olkiewicz, D. Verbel, S. D. Kuduk, J. B. Schwarz, D. Sames, S. Danishefsky, P. O. Livingston, et al. Fully Synthetic Carbohydrate-Based Vaccines in Biochemically Relapsed Prostate Cancer: Clinical Trial Results With {alpha}-N-Acetylgalactosamine-O-Serine/Threonine Conjugate Vaccine J. Clin. Oncol., December 1, 2003; 21(23): 4292 - 4298. [Abstract] [Full Text] [PDF]

				H. S. Silverman, M. Sutton-Smith, K. McDermott, P. Heal, S.-H. Leir, H. R. Morris, M. A. Hollingsworth, A. Dell, and A. Harris The contribution of tandem repeat number to the O-glycosylation of mucins Glycobiology, April 1, 2003; 13(4): 265 - 277. [Abstract] [Full Text] [PDF]

				E. Barbera-Guillem, J. K. Nyhus, C. C. Wolford, C. R. Friece, and J. W. Sampsel Vascular Endothelial Growth Factor Secretion by Tumor-infiltrating Macrophages Essentially Supports Tumor Angiogenesis, and IgG Immune Complexes Potentiate the Process Cancer Res., December 1, 2002; 62(23): 7042 - 7049. [Abstract] [Full Text] [PDF]

				V. Kudryashov, P. W. Glunz, L. J. Williams, S. Hintermann, S. J. Danishefsky, and K. O. Lloyd Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewisy conjugates in mice PNAS, March 13, 2001; 98(6): 3264 - 3269. [Abstract] [Full Text] [PDF]

				R. Lo-Man, S. Vichier-Guerre, S. Bay, E. Deriaud, D. Cantacuzene, and C. Leclerc Anti-Tumor Immunity Provided by a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri-Tn Glycotope J. Immunol., February 15, 2001; 166(4): 2849 - 2854. [Abstract] [Full Text] [PDF]

				E. C. M. Brinkman-Van der Linden and A. Varki New Aspects of Siglec Binding Specificities, Including the Significance of Fucosylation and of the Sialyl-Tn Epitope J. Biol. Chem., March 17, 2000; 275(12): 8625 - 8632. [Abstract] [Full Text] [PDF]

				R. Lo-Man, S. Bay, S. Vichier-Guerre, E. Deriaud, D. Cantacuzene, and C. Leclerc A Fully Synthetic Immunogen Carrying a Carcinoma-associated Carbohydrate for Active Specific Immunotherapy1 Cancer Res., April 1, 1999; 59(7): 1520 - 1524. [Abstract] [Full Text] [PDF]